Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05224141 · ClinicalTrials.gov registry record · Phase 3
Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)
A Phase 3 study of Small Cell Lung Carcinoma, sponsored by Merck Sharp & Dohme.
- Active
- Registry status
- Phase 3
- Development phase
- 460
- Enrollment target
- 20
- Study locations
NCT05224141 is a Phase 3 study of Small Cell Lung Carcinoma that is active but no longer recruiting, run by Merck Sharp & Dohme. The registered enrollment target is 460 participants, above the 235-participant average among 18 other Small Cell Lung Carcinoma trials with a reported enrollment target (96% higher). The trial reports 20 study locations across 14 states.
The verdict
NCT05224141, a Phase 3 study of Small Cell Lung Carcinoma, is active but no longer recruiting, sponsored by Merck Sharp & Dohme.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 460 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the combination of a fixed dose pembrolizumab/vibostolimab co-formulation (MK-7684A) with etoposide/platinum chemotherapy followed by MK-7684A compared to the combination of atezolizumab with etoposide/platinum chemotherapy followed by atezolizumab in the first-line treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC). The primary hypothesis is, with respect to overall survival, MK-7684A in combination with the background therapy of etoposide/platinum followed by MK-7684A, is superior to atezolizumab in combination with the background therapy of etoposide/platinum followed by atezolizumab.
Conditions Studied
Interventions
- BIOLOGICAL Atezolizumab
- DRUG Cisplatin
- DRUG Etoposide
- DRUG Saline placebo
- BIOLOGICAL Pembrolizumab/Vibostolimab Co-Formulation
Study Locations (20)
California
- Los Angeles Hematology Oncology Medical Group ( Site 0006) - Los Angeles
- VA West Los Angeles Medical Center ( Site 0004) - Los Angeles
Virginia
- Blue Ridge Cancer Care ( Site 0015) - Blacksburg
- University of Virginia Cancer Center ( Site 0019) - Charlottesville
Buenos Aires
- Hospital Italiano de Buenos Aires-Clinical Oncology ( Site 0203) - Ciudad Autonoma de Buenos Aires
- Instituto de Investigaciones Clínicas Mar del Plata ( Site 0201) - Mar del Plata
Santa Fe Province
- Hospital Provincial del Centenario ( Site 0205) - Rosario
- Sanatorio Parque ( Site 0202) - Rosario
New South Wales
- Nepean Hospital ( Site 2700) - Kingswood
- Calvary Mater Newcastle ( Site 2703) - Waratah
Victoria
- Frankston Hospital-Oncology and Haematology ( Site 2702) - Frankston
- Western Health-Sunshine & Footscray Hospitals-Cancer Services-Cancer Research ( Site 2701) - Melbourne
Alabama
- Infirmary Cancer Care ( Site 0022) - Mobile
Florida
- Boca Raton Regional Hospital-Lynn Cancer Institute ( Site 0014) - Boca Raton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 460 participants |
| Start Date | 2022-03-24 |
| Est. Completion | 2027-06-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05224141
The ClinicalTrials.gov registry entry for NCT05224141 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 460 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 235-participant average among 18 other Small Cell Lung Carcinoma trials with a reported enrollment target (96% higher). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Small Cell Lung Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Atezolizumab is the first listed.
NCT05224141 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Virginia, Buenos Aires.
Frequently Asked Questions
What is clinical trial NCT05224141 about?
NCT05224141 is a clinical study titled "Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)". This study will evaluate the combination of a fixed dose pembrolizumab/vibostolimab co-formulation (MK-7684A) with etoposide/platinum chemotherapy followed by MK-7684A compared to the combination of atezolizumab with etoposide/platinum chemotherapy followed by atezolizumab in the first-line treatmen...
What is the current status of trial NCT05224141?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 460 participants. The study started on 2022-03-24. Estimated completion is 2027-06-07.
What conditions does trial NCT05224141 study?
This clinical trial studies the following conditions: Small Cell Lung Carcinoma.
What interventions are being tested in trial NCT05224141?
The interventions under investigation include: Atezolizumab (BIOLOGICAL), Cisplatin (DRUG), Etoposide (DRUG), Saline placebo (DRUG), Pembrolizumab/Vibostolimab Co-Formulation (BIOLOGICAL).
Who is sponsoring clinical trial NCT05224141?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05224141 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Indiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small Cell Lung Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone
COMPLETED · Phase 3
-
A Study of Hospital-at-Home for People Receiving Tarlatamab
RECRUITING · NA
-
Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer
RECRUITING · Early Phase 1
-
A Study of LY4175408 in Participants With Advanced Cancer
RECRUITING · Phase 1
-
Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer
RECRUITING · Phase 2
-
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.